Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome</title><author><name sortKey="Baranovich, Tatiana" sort="Baranovich, Tatiana" uniqKey="Baranovich T" first="Tatiana" last="Baranovich">Tatiana Baranovich</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Jones, Jeremy C" sort="Jones, Jeremy C" uniqKey="Jones J" first="Jeremy C." last="Jones">Jeremy C. Jones</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Russier, Marion" sort="Russier, Marion" uniqKey="Russier M" first="Marion" last="Russier">Marion Russier</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Vogel, Peter" sort="Vogel, Peter" uniqKey="Vogel P" first="Peter" last="Vogel">Peter Vogel</name><affiliation><nlm:aff id="aff2">Department of Veterinary Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Szretter, Kristy J" sort="Szretter, Kristy J" uniqKey="Szretter K" first="Kristy J." last="Szretter">Kristy J. Szretter</name><affiliation><nlm:aff id="aff3">Visterra, Inc., Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Sloan, Susan E" sort="Sloan, Susan E" uniqKey="Sloan S" first="Susan E." last="Sloan">Susan E. Sloan</name><affiliation><nlm:aff id="aff3">Visterra, Inc., Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Seiler, Patrick" sort="Seiler, Patrick" uniqKey="Seiler P" first="Patrick" last="Seiler">Patrick Seiler</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Trevejo, Jose M" sort="Trevejo, Jose M" uniqKey="Trevejo J" first="Jose M." last="Trevejo">Jose M. Trevejo</name><affiliation><nlm:aff id="aff3">Visterra, Inc., Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Webby, Richard J" sort="Webby, Richard J" uniqKey="Webby R" first="Richard J." last="Webby">Richard J. Webby</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Govorkova, Elena A" sort="Govorkova, Elena A" uniqKey="Govorkova E" first="Elena A." last="Govorkova">Elena A. Govorkova</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26787699</idno><idno type="pmc">4808199</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808199</idno><idno type="RBID">PMC:4808199</idno><idno type="doi">10.1128/AAC.02457-15</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000047</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000047</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome</title><author><name sortKey="Baranovich, Tatiana" sort="Baranovich, Tatiana" uniqKey="Baranovich T" first="Tatiana" last="Baranovich">Tatiana Baranovich</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Jones, Jeremy C" sort="Jones, Jeremy C" uniqKey="Jones J" first="Jeremy C." last="Jones">Jeremy C. Jones</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Russier, Marion" sort="Russier, Marion" uniqKey="Russier M" first="Marion" last="Russier">Marion Russier</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Vogel, Peter" sort="Vogel, Peter" uniqKey="Vogel P" first="Peter" last="Vogel">Peter Vogel</name><affiliation><nlm:aff id="aff2">Department of Veterinary Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Szretter, Kristy J" sort="Szretter, Kristy J" uniqKey="Szretter K" first="Kristy J." last="Szretter">Kristy J. Szretter</name><affiliation><nlm:aff id="aff3">Visterra, Inc., Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Sloan, Susan E" sort="Sloan, Susan E" uniqKey="Sloan S" first="Susan E." last="Sloan">Susan E. Sloan</name><affiliation><nlm:aff id="aff3">Visterra, Inc., Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Seiler, Patrick" sort="Seiler, Patrick" uniqKey="Seiler P" first="Patrick" last="Seiler">Patrick Seiler</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Trevejo, Jose M" sort="Trevejo, Jose M" uniqKey="Trevejo J" first="Jose M." last="Trevejo">Jose M. Trevejo</name><affiliation><nlm:aff id="aff3">Visterra, Inc., Cambridge, Massachusetts, USA</nlm:aff></affiliation></author><author><name sortKey="Webby, Richard J" sort="Webby, Richard J" uniqKey="Webby R" first="Richard J." last="Webby">Richard J. Webby</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author><author><name sortKey="Govorkova, Elena A" sort="Govorkova, Elena A" uniqKey="Govorkova E" first="Elena A." last="Govorkova">Elena A. Govorkova</name><affiliation><nlm:aff id="aff1">Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Antimicrobial Agents and Chemotherapy</title><idno type="ISSN">0066-4804</idno><idno type="eISSN">1098-6596</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Most cases of severe influenza are associated with pulmonary complications, such as acute respiratory distress syndrome (ARDS), and no antiviral drugs of proven value for treating such complications are currently available. The use of monoclonal antibodies targeting the stem of the influenza virus surface hemagglutinin (HA) is a rapidly developing strategy for the control of viruses of multiple HA subtypes. However, the mechanisms of action of these antibodies are not fully understood, and their ability to mitigate severe complications of influenza has been poorly studied. We evaluated the effect of treatment with VIS410, a human monoclonal antibody targeting the HA stem region, on the development of ARDS in BALB/c mice after infection with influenza A(H7N9) viruses. Prophylactic administration of VIS410 resulted in the complete protection of mice against lethal A(H7N9) virus challenge. A single therapeutic dose of VIS410 given 24 h after virus inoculation resulted in dose-dependent protection of up to 100% of mice inoculated with neuraminidase inhibitor-susceptible or -resistant A(H7N9) viruses. Compared to the outcomes in mock-treated controls, a single administration of VIS410 improved viral clearance from the lungs, reduced virus spread in lungs in a dose-dependent manner, resulting in a lower lung injury score, reduced the extent of the alteration in lung vascular permeability and protein accumulation in bronchoalveolar lavage fluid, and improved lung physiologic function. Thus, antibodies targeting the HA stem can reduce the severity of ARDS and show promise as agents for controlling pulmonary complications in influenza.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob. Agents Chemother</journal-id><journal-id journal-id-type="hwp">aac</journal-id><journal-id journal-id-type="pmc">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26787699</article-id><article-id pub-id-type="pmc">4808199</article-id><article-id pub-id-type="publisher-id">02457-15</article-id><article-id pub-id-type="doi">10.1128/AAC.02457-15</article-id><article-categories><subj-group subj-group-type="heading"><subject>Antiviral Agents</subject></subj-group></article-categories><title-group><article-title>The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome</article-title><alt-title alt-title-type="running-head">VIS410 Efficacy against Severe A(H7N9) Influenza</alt-title><alt-title alt-title-type="short-authors">Baranovich et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baranovich</surname><given-names>Tatiana</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Jeremy C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Russier</surname><given-names>Marion</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vogel</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Szretter</surname><given-names>Kristy J.</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sloan</surname><given-names>Susan E.</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seiler</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Trevejo</surname><given-names>Jose M.</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Webby</surname><given-names>Richard J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Govorkova</surname><given-names>Elena A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><label>a</label>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</aff><aff id="aff2"><label>b</label>Department of Veterinary Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA</aff><aff id="aff3"><label>c</label>Visterra, Inc., Cambridge, Massachusetts, USA</aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Susan E. Sloan, <email>ssloan@visterrainc.com</email>, or Elena A. Govorkova, <email>elena.govorkova@stjude.org</email>.</corresp><fn id="fn1" fn-type="present-address"><label>*</label><p>Present address: Tatiana Baranovich, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, and Carter Consulting, Inc., Atlanta, Georgia, USA.</p></fn><fn fn-type="other"><p><bold>Citation</bold> Baranovich T, Jones JC, Russier M, Vogel P, Szretter KJ, Sloan SE, Seiler P, Trevejo JM, Webby RJ, Govorkova EA. 2016. The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome. Antimicrob Agents Chemother 60:2118–2131. doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.02457-15">10.1128/AAC.02457-15</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>19</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>25</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2016</year></pub-date><volume>60</volume><issue>4</issue><fpage>2118</fpage><lpage>2131</lpage><history><date date-type="received"><day>9</day><month>10</month><year>2015</year></date><date date-type="rev-request"><day>2</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016, American Society for Microbiology. All Rights Reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>American Society for Microbiology</copyright-holder></permissions><self-uri content-type="pdf" xlink:href="zac00416002118.pdf"></self-uri><abstract><p>Most cases of severe influenza are associated with pulmonary complications, such as acute respiratory distress syndrome (ARDS), and no antiviral drugs of proven value for treating such complications are currently available. The use of monoclonal antibodies targeting the stem of the influenza virus surface hemagglutinin (HA) is a rapidly developing strategy for the control of viruses of multiple HA subtypes. However, the mechanisms of action of these antibodies are not fully understood, and their ability to mitigate severe complications of influenza has been poorly studied. We evaluated the effect of treatment with VIS410, a human monoclonal antibody targeting the HA stem region, on the development of ARDS in BALB/c mice after infection with influenza A(H7N9) viruses. Prophylactic administration of VIS410 resulted in the complete protection of mice against lethal A(H7N9) virus challenge. A single therapeutic dose of VIS410 given 24 h after virus inoculation resulted in dose-dependent protection of up to 100% of mice inoculated with neuraminidase inhibitor-susceptible or -resistant A(H7N9) viruses. Compared to the outcomes in mock-treated controls, a single administration of VIS410 improved viral clearance from the lungs, reduced virus spread in lungs in a dose-dependent manner, resulting in a lower lung injury score, reduced the extent of the alteration in lung vascular permeability and protein accumulation in bronchoalveolar lavage fluid, and improved lung physiologic function. Thus, antibodies targeting the HA stem can reduce the severity of ARDS and show promise as agents for controlling pulmonary complications in influenza.</p></abstract><funding-group><award-group id="award1"><funding-source id="gs1">HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
<named-content content-type="funder-id">http://dx.doi.org/10.13039/100000060</named-content></funding-source><award-id rid="gs1">HHSN272201400006C</award-id><principal-award-recipient>Richard J. Webby</principal-award-recipient></award-group><funding-statement>The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><counts><fig-count count="6"></fig-count><table-count count="3"></table-count><equation-count count="0"></equation-count><ref-count count="51"></ref-count><page-count count="14"></page-count><word-count count="11213"></word-count></counts></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000047 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000047 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |